AI in Neuroscience: Partnering with DANNCE.AI to Increase Drug Efficacy & Improve the Lives of People with Movement Disorders
/DANNCE.AI is bringing to market a novel phenotyping platform to digitize the clinical assessments used by clinicians and drug developers to quantify movement. We led their $2.6M pre-seed round along with co-investors Glasswing Ventures, The Leo Lion Company, Duke Capital Partners, and Merck Digital Sciences Studio.
Read More